On October 24, 2025, Eli Lilly announced new clinical results for EBGLYSS (lebrikizumab-lbkz), showing durable disease control in moderate-to-severe atopic dermatitis with less frequent dosing, and submitted these findings to the FDA for a potential label update. Additional results for baricitinib, developed with Incyte, demonstrated near-complete scalp hair regrowth in patients with alopecia areata. LLY stock closed at $821.04 on October 23, 2025, up 1.06%, and is trading at $820.90 pre-market (-0.02%). There is no indication that today's clinical news has driven a major price move, and the stock appears to be trading in line with recent trends.